Informed Design

To inform the design of our platform, we conducted extensive research in the areas of malarial diagnosis, infectious diseases as well as policy surrounding diagnostic tests internationally. We reached out to many professionals working in various areas to best understand all sides of this issue. We were able to speak with and interview:

Dr. Lisa Allen Scott

Holding a PhD in Population and Public Health, Dr. Allen Scott currently works at the University of Calgary and was a great resource to us when designing our project. As one of our first stops when we were seeking to understand the problem at hand, her experiences were exactly what we needed. Having spent significant amounts of time in rural villages in Tanzania, Dr. Allen Scott investigated a seemingly inflated rate of malaria diagnosis. What she found was that nearly 70% of individuals were diagnosed as having malaria when they actually didn't. She has written several papers on the issue, as well as proposed solutions. Dr. Allen Scott played a huge role in designing a set of desired characteristics that our diagnostic device must have.

Dr. Abebe Bayih

Dr. Bayih is an expert in the field of infectious diseases. Currently he is testing novel anti-malarial drugs in animals.

• Dr. Abolarin worked as a surgeon in Nigeria for 10 years before relocating to Canada where he now serves as a family medical physician.

Each of these professionals provided insight into different areas of the project. They helped us to better understand the needs in the areas we would be targeting, as well as helping us to recognize potential obstacles.

In addition, we reached out to some friends of one our team members who previously lived in Kikaaya, Uganda. We connected with Derrick Luwaga who runs a non-profit organization (KACCAD) and medical clinic in a rural village. Derrick was able to speak with both the technicians and the physicians who work within the lab conducting malarial diagnosis. He sent us videos of the interviews he conducted, the process involved as well as documenting the available technology and resources. This was an amazing insight to have to guide our project, and to even better understand the needs of the end-user.

With all of this in mind we determined that our diagnostic tool would need to have several characteristics:

• Robust
Our final device must be able to withstand transport as well as harsh environmental conditions. To make our device as robust as possible, we have used B. subtilis spores. These spores can withstand extreme heat and cold before their rehydration, and provide us with the necessary shelf life required by the World Health Organization (2 years).
• Affordable
It is of utmost importance that our system be attainable by our end user. Although no current multiplexed standard exists, we have used the pricing suggested by the WHO for an HIV assay, which is a final device cost of no more than $10USD. Our consultation with FIND helped us realize the number of taxes that will be applied to our device, essentially doubling its original cost. For this reason we seek a final device price of no more than $5 per device.
• Adaptable
Our device must be easily tailored to diagnose diseases endemic to a particular area. By simply changing the target sequence within our B. subtilis strain we are able to target different pathogens that might plague different geographical regions. This device could easily have different versions for different areas.
• Easy to Use
Not all rural clinics have trained technicians. For this reason our device must be simple, requiring very little expertise. In addition, our device overcomes language barriers by displaying only colorimetric results. These results are clear and defined, leaving little room for misinterpretation.

Foundation for Innovative New Diagnostics (FIND)



While abroad attending the Biological and Toxin Weapons Convention (BTWC), the iGEM Calgary arranged a meeting the Foundation for Innovative New Diagnostics (FIND), the foremost authority on non-profit diagnostic systems internationally. We sought to meet with them to better understand the world of diagnostics, as well as seeking their opinion regarding the feasibility and demand for the proposed device.

Our meeting with Dr. Ranald Sutherland proved to be insightful and informative. We learned how you could expect that the consumer cost of a device will be nearly double that of production costs once all taxes and fees are levied. He also advised the team to redirect their focus from being simply a multidiagnostic, to a ‘reflex test’. A ‘reflex test’ would be administered only when presented with a negative diagnosis from a rapid malaria diagnostic, which functions much more quickly then the assay being designed. This is an important marketing tool, as if they were to try and compete with these already existing and highly efficient technologies, the project might not prevail.

FIND has offered to be a continued resource for our team should they have any more concerns or questions. Their consultation has given the team a strategy for creating a novel, yet practical diagnostic tool.